442134-72-7 Usage
Uses
Used in Pharmaceutical Industry:
2,3-DIFLUORO-6-AMINOBENZOIC ACID is used as a key intermediate in the synthesis of 2-[[2-(phenylamino)-1H-pyrrolo[2,3-d]pyrimidin-4-yl]amino] benzamide derivatives. These derivatives serve as inhibitors of IGF-1R (Insulin-like Growth Factor 1 Receptor) and IR (Insulin Receptor) receptor tyrosine kinase, playing a crucial role in the development of anticancer agents.
The inhibition of IGF-1R and IR receptor tyrosine kinase by these benzamide derivatives can effectively suppress the growth and proliferation of cancer cells, making them potential candidates for the treatment of various types of cancer. By targeting these receptors, these agents can disrupt the signaling pathways that promote cell survival, growth, and metastasis, thereby offering a promising therapeutic approach for cancer management.
Check Digit Verification of cas no
The CAS Registry Mumber 442134-72-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,2,1,3 and 4 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 442134-72:
(8*4)+(7*4)+(6*2)+(5*1)+(4*3)+(3*4)+(2*7)+(1*2)=117
117 % 10 = 7
So 442134-72-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H5F2NO2/c8-3-1-2-4(10)5(6(3)9)7(11)12/h1-2H,10H2,(H,11,12)
442134-72-7Relevant academic research and scientific papers
POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS
-
Page/Page column 110; 111; 112, (2018/07/29)
The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.
2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER
-
Page/Page column 74, (2009/04/25)
Novel pyrrolopyrimidines as shown in formula (I) and pharmaceutically acceptable derivatives thereof. The compounds are useful in the inhibition of IGF-1R.
